Highest-materiality recent filing
Codexis raises ~$23.1M in public offering of 16.7M shares at $1.50/share
Issued 16,666,667 shares of common stock at $1.50 per share in an underwritten public offering.
Codexis Q1 revenue doubles to $15.2M; net loss narrows to $8.7M from $20.7M
Revenue $15.2M (up from $7.5M YoY); product gross margin 71% vs 55%.
Codexis Q4 revenue jumps 81% to $38.9M, net income of $9.6M; FY2025 revenue up 19%
Q4 2025 revenue of $38.9M (up 81% YoY); net income $9.6M vs net loss of $10.4M in Q4 2024.
Codexis appoints Alison Moore CEO, cuts 24% workforce, signs $37.8M Merck deal; Q3 net loss $19.6M
Alison Moore appointed President and CEO effective Nov 7, 2025; Stephen Dilly becomes Executive Chairman.
Codexis Q2 revenue $15.3M beats consensus; net loss narrows to $13.3M from $22.8M YoY
Revenue $15.3M, beating $14.1M analyst consensus; net loss $13.3M ($0.16/sh) vs $22.8M ($0.32/sh) YoY.
Codexis Q1 revenue drops to $7.5M from $17.1M; net loss widens to $20.7M
Revenue $7.5M vs $17.1M in Q1 2024; decline due to $6M one-time Roche license and large orders in prior year.
Codexis FY2024 revenue $59.3M, net loss $65.3M; guides 2025 revenue $64M-$68M
FY2024 total revenue $59.3M (-4% YoY ex-PAXLOVID); net loss $65.3M ($0.89/share) vs $76.2M ($1.12) in FY2023.
Codexis Q3 product rev $11.2M, net loss narrows to $20.6M; cash $90.3M
Total revenues $12.8M vs $9.3M YoY; product rev $11.2M vs $5.4M; R&D rev $1.7M vs $3.9M.
Codexis appoints Alison Moore as CTO and Georgia Erbez as CFO effective Sept 30, 2024
Alison Moore, formerly a Board member, becomes CTO; resigned from Board and committees.
Codexis Q2 revenues fall 62% YoY to $8.0M; net loss widens; reiterates FY2024 guidance
Q2 total revenue $8.0M vs $21.3M YoY; product rev $6.3M vs $11.0M; R&D rev $1.7M vs $10.3M.
Successfully synthesized a full-length siRNA oligonucleotide using ECO Synthesis enzymatic platform, including a conjugation moiety.
Codexis Q1 revenue up 32%, net loss narrows to $11.5M; reiterates FY guidance
Total revenue $17.1M (+32% YoY); product revenue $9.6M (+14%); net loss $11.5M vs $22.6M loss in Q1 2023.
Q4 net loss $7.2M ($0.10/sh); FY2023 net loss $76.2M ($1.12/sh). Excl PAXLOVID & impairment, adj FY net loss $50.8M ($0.74/sh).
Codexis secures up to $40M term loan from Innovatus; $30M funded
First tranche of $30M funded on Feb 13, 2024; second $10M tranche available on milestones.
Codexis assigns CDX-7108 to Nestlé for $5M upfront plus milestones; closing expected Jan 5
Upfront payment of $5M, potential $15M development milestones, $25M commercial milestones, and royalty on net sales above baseline.
Codexis revises restructuring costs; records $9.2M asset impairment on facility
Workforce reduction of ~25% completed by Sept 30, 2023; actual severance costs $3.1M vs. expected $2.9M.
Codexis Q3 net loss widens to $34.9M; revenue ex-PAXLOVID falls 57% to $9.3M
Net loss of $34.9M ($0.50/share) vs $10.0M loss ($0.15) in Q3 2022; adjusted loss $17.9M ($0.26) excludes restructuring/impairments.
Codexis Q2 loss widens to $11.5M; pivots to ECO Synthesis RNAi platform, cuts headcount 25%
Net loss of $11.5M ($0.17/share) vs $2.6M loss in Q2 2022; total rev $21.3M (ex-PAXLOVID up 46% YoY).
Codexis reduces headcount 25%, extends cash runway to mid-2026; Q2 preliminary revenue $21-22M
Workforce reduction of ~25% (approx. $2.9M expense in Q3 2023); expects completion by Sep 30, 2023.
Codexis shareholders approve doubling authorized shares to 200M, new ESPP, and 2019 plan amendment
Shareholders approved certificate amendment to increase authorized common shares from 100M to 200M.
Codexis Q1 revenue $13M (-63% YoY); net loss $22.6M; lowers product revenue guidance
Q1 total revenue $13.0M (ex-PAXLOVID -8% YoY); net loss $22.6M ($0.34/share) vs $8.4M loss in Q1 2022.
FY2022 total revenue $138.6M (+32% YoY); ex-PAXLOVID revenue $63.2M (-10% YoY). Net loss $33.6M ($0.51/share) vs $21.3M loss in 2021.
Codexis cuts 18% of workforce, discontinues development programs; $2.9M severance cost
Workforce reduction of approximately 18% authorized on November 28, 2022.
Codexis Q3 2022 revenue $34.5M, net loss $10.0M; reaffirms FY2022 guidance
Total Q3 revenue $34.5M, down 6% YoY from $36.8M; net loss $10.0M ($0.15/share) vs net income $2.2M in Q3 2021.
Codexis appoints Kevin Norrett as COO and Rahul Singhvi to board
Kevin Norrett named COO effective Oct 3, 2022; base salary $450k, 50% target bonus.
Codexis Q2 revenue up 51% to $38.4M; CEO Nicols to retire; Dilly appointed
Product revenue surged 135% YoY to $34.6M, driven by Pfizer PAXLOVID enzyme sales.
Codexis appoints Dr. Stephen Dilly as CEO, succeeding John Nicols who retires
Dr. Stephen Dilly appointed President & CEO effective Aug 9, 2022; replaces John Nicols retiring Aug 8.
Codexis cuts FY2022 revenue guidance to $135M-$141M; preliminary Q2 revenue ~$38M
Preliminary Q2 2022 total revenue ~$38M; full-year guidance reduced to $135M-$141M.
Codexis signs 10-year supply deal with Pfizer for PAXLOVID enzyme CDX-616; receives $25.9M retainer
Supply Agreement covers Codexis enzyme CDX-616 used in Pfizer's PAXLOVID (nirmatrelvir).
On April 4, 2025, Byron L. Dorgan provided notice to the board of directors (the “Board”) of Codexis, Inc. (the “Company”) of his intention to retire and not to stand for reelection to the Board at the expiration of his current term at the Company’s 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”).
On March 28, 2025, the Board of Directors (the “Board”) of Codexis, Inc. (the “Company”), upon the recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Cynthia Collins as a member of the Board as a Class II director, effective immediately.
On January 14, 2025, the Board of Directors (the “Board”) of Codexis, Inc. (the “Company”), upon the recommendation of the Board’s Nominating and Corporate Governance Committee (the “Nominating and Corporate Governance Committee”), appointed Christos Richards as a member of the Board as a Class II director, effective immediately.
appointed Raymond De Vré as a member of the Board as a Class I director, effective immediately.
Sriram Ryali ceased to serve as the Company’s Chief Financial Officer and principal financial and accounting officer effective as of September 30, 2024.
In connection with her appointment as Chief Technical Officer, Dr. Moore resigned from the Board and its committees, effective as of September 30, 2024.
On September 30, 2024, the Board appointed Georgia Erbez as the Company’s Chief Financial Officer, replacing Sriram Ryali in such role, effective September 30, 2024.
On September 30, 2024, the Board appointed Georgia Erbez as the Company’s Chief Financial Officer, replacing Sriram Ryali in such role, effective September 30, 2024.
On September 30, 2024, the board of directors (the “Board”) of Codexis, Inc. (the “Company” or “Codexis”) appointed Alison Moore, Ph.D., a current member of the Board, to serve as the Company’s Chief Technical Officer.
On February 13, 2024, Jennifer Aaker, Ph.D. provided notice to the board of directors (the “Board”) of Codexis, Inc. (the “Company”) of her intention not to stand for reelection to the Board at the expiration of her current term at the Company’s 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”).
On March 29, 2023, Patrick Y. Yang, Ph.D. provided notice to the board of directors (the “Board”) of Codexis, Inc. (the “Company”) of his intention not to stand for reelection to the Board at the expiration of his current term at the 2023 annual meeting of stockholders.
Ross Taylor ceased to serve as the Company’s Chief Financial Officer and principal financial and accounting officer effective as of the date thereof.
Max materiality 0.80 · Median 0.60 · Most common event earnings